Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.41 |
| ▸ | RBP4 | P02753 | 3/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272643 | 0.84 | RBP4 (0.53) | PTGDR2PTGDRRBP4PROKR1 | |
| SCHEMBL2278508 | 0.84 | DRD2 (0.60) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL11906574 | 0.80 | PTGDR2 (0.47) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL2274727 | 0.79 | PROKR1 (0.43) | RBP4PROKR1 | |
| SCHEMBL11891679 | 0.79 | PTGDR2 (0.55) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL2277918 | 0.75 | HSD11B1 (0.46) | RBP4PROKR1 | |
| SCHEMBL2719593 | 0.74 | RBP4 (0.41) | RBP4 | |
| SCHEMBL27651112 | 0.74 | PTGDR2 (0.47) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5768898 | 0.74 | PROKR1 (0.46) | PROKR1 | |
| SCHEMBL2278132 | 0.71 | CCR5 (0.42) | PTGDR2PTGDRRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR1A, HTR2A, HTR6 | DRD2 124/4885DRD1 327/4885DRD4 221/4885 |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | HTR1A, HTR6, HTR2A | DRD2 100/4885DRD1 301/4885DRD4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.